Study of UK key workers shows around half who had COVID-19 symptoms probably did not have the disease

September 24, 2020

New research from Public Health England (PHE) presented at this week's ESCMID Conference on Coronavirus Disease (ECCVID) shows up to half of UK key workers from a cohort of just under 3,000 individuals recruited (including police, fire and healthcare workers) who had self-reported symptoms of COVID-19 did not test positive for antibodies to the disease. This suggests that their symptoms were due to other conditions. The study was presented by Ranya Mulchandani, PHE, Birmingham, UK in collaboration with PHE colleagues and academic partners across the UK.

Screening for SARS-CoV-2 antibodies is under way in some key worker groups; however, how this adds to self-reported COVID-19 illness is unclear. In this study, the team investigated the association between self-reported belief of COVID-19 illness and seropositivity.

The authors carried out a study of three key worker groups which took place at six acute NHS hospitals and two Police and Fire & Rescue sites across England in June 2020. They recruited individuals from three streams: (A) Police and Fire (B) healthcare workers and (C) healthcare workers with previously positive PCR result for COVID-19 (this last group was used to assess the immunoassay sensitivities, namely the ability of the antibody tests to correctly identify those with SARS-CoV-2 antibodies or 'true positive' rate.

The team used a study-specific questionnaire to collect self-reported signs and symptoms of COVID-19 and compared this with serology results from two SARS-CoV2 immunoassays (Nucleoprotein - Roche Elecsys ® and Spike-protein - EUROIMMUN).

Between 01 and 26 June, 2847 individuals were recruited: 1147 from Stream A, 1546 from Stream B and 154 from Stream C. 943 of the 2847 participants (33%) reported belief they had had COVID-19, having experienced compatible symptoms; however, 466 (49%) of these were seronegative on both antibody assays, meaning it is very unlikely they had had COVID-19. The Roche Elecsys ® and EUROIMMUN assays had 96.6% and 93.3% sensitivity respectively.

The researchers found that symptomatic but seronegative individuals had significantly earlier dates of symptom onset than the symptomatic seropositive individuals, shorter illness duration and a much lower reporting frequency of anosmia (lost of sense of taste and smell).

Self-reported belief of COVID-19 was common among the frontline worker cohort. About half of these individuals were seronegative, despite a high sensitivity (accuracy) of serology in this cohort, at least in individuals with previous positive PCR results. These data suggest that self-reported symptoms substantially overestimate COVID-19 disease relative to serology, and that in the key worker cohort studied, many mistook non-COVID-19 respiratory disease, particularly during the early part of the COVID-19 outbreak, as COVID-19.

Ranya Mulchandani, UK-FETP Field Epidemiology Fellow at Public Health England and the study's lead author, said: "In the course of this study, we tested just under a thousand people who thought they had had COVID-19 due to compatible symptoms. We found that half of them lacked any evidence of having had the infection, testing negative for the presence of antibodies. This was also true for a substantial number of frontline health workers. Although these findings are still subject to peer review, it is possible that a large number of people in the general population incorrectly believe that they have already had COVID-19. It is crucial that people do not get complacent and continue to observe government health advice, including social distancing and good hand hygiene, even if they think they have been infected in the past."

European Society of Clinical Microbiology and Infectious Diseases

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to